2024
Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials.
Aung T, Zhang C, Espinoza G, Leung L, Moon J, Horst B, Ferringer T, Nastiuk K, Rimm D, Saenger Y. Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials. Journal Of Clinical Oncology 2024, 42: 9567-9567. DOI: 10.1200/jco.2024.42.16_suppl.9567.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesRecurrence free survivalAmerican Joint Committee on CancerFree survivalInfiltrating lymphocytesRetrospective cohortClinical trialsQuantify tumor-infiltrating lymphocytesStage II-III melanomaTumor-infiltrating lymphocytes groupDiagnostic slidesIIb-IIIaRoswell Park Comprehensive Cancer CenterEarly-stage melanoma patientsCox modelStage IIB-IIICAdjuvant clinical trialsKaplan-Meier curvesMultivariate Cox modelUnivariate Cox modelCox proportional hazards modelsClinical pathological featuresGeisinger Medical CenterProportional hazards modelClinical trial design
2021
Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma
Johannet P, Coudray N, Donnelly DM, Jour G, Illa-Bochaca I, Xia Y, Johnson DB, Wheless L, Patrinely JR, Nomikou S, Rimm DL, Pavlick AC, Weber JS, Zhong J, Tsirigos A, Osman I. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. Clinical Cancer Research 2021, 27: 131-140. PMID: 33208341, PMCID: PMC7785656, DOI: 10.1158/1078-0432.ccr-20-2415.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDisease ProgressionDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedImmune Checkpoint InhibitorsMachine LearningMaleMelanomaMiddle AgedNeoplasm StagingPrognosisProgression-Free SurvivalProspective StudiesRisk AssessmentROC CurveSkinSkin NeoplasmsConceptsProgression-free survivalImmune checkpoint inhibitorsLower riskClinicodemographic characteristicsAdvanced melanomaClinical dataWorse progression-free survivalICI treatment outcomesKaplan-Meier curvesBiomarkers of responseStandard of careCheckpoint inhibitorsICI responseImmunotherapy responseValidation cohortTraining cohortDisease progressionProspective validationTreatment outcomesHigh riskClinical practicePatientsROC curveProgressionRisk